Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 147

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 147
---
 table shows
the public offering price, placement agent fees and proceeds, before expenses, to us, assuming the purchase of all the securities we are
offering.

|                                  |     | Per Unit |     | Per Pre-Funded Unit |     | Total |
|:---------------------------------|:----|:---------|:----|:--------------------|:----|:------|
| Public offering price            |     | $        |     | $                   |     | $     |
| Placement agent fees             |     | $        |     | $                   |     | $     |
| Proceeds, before expenses, to us |     | $        |     | $                   |     | $     |

Placement Agent Warrants

The
placement agent intends to purchase Placement Agent Warrants to purchase up to a number of Depositary Shares equal to 5.0% of the units
sold in this offering for $1.995 per warrant. The Placement Agent Warrants will have an exercise price equal to 225% of the offering
price per Unit, subject to customary anti-dilution provisions consistent with FINRA Rule 5110(g)(8). The Placement Agent Warrants will
be substantially similar to the Series L Warrants issued hereunder. As with the Series L Warrants, the Placement Agent Warrants will
expire two and a half (2.5) years after the issuance date and do not provide for any registration rights. The Placement Agent Warrants
and the Depositary Shares (representing Ordinary Shares) are being registered on the registration statement of which this prospectus
is a part.

If all of the Placement
Agents Warrants are exercised on a zero cash exercise price basis at the floor price, an aggregate of 265,225,900,000 Ordinary Shares
(in the form of Depositary Shares) would be issued upon such zero cash exercise without payment to the Company of any additional cash.

| 84 |

The Placement Agent Warrants and underlying
shares have been deemed compensation by FINRA. Pursuant to FINRA Rule 5110(e)(1), underwriting compensation consisting of securities must
not be sold, transferred, assigned, pledged or hypothecated nor may they be the subject of any hedging, short sale, derivative, put or
call transaction that would result in the economic disposition of the securities by any person for a period of 180 days following the
commencement of sales of this offering except to any placement agent and selected dealer participating in the offering and their